Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × vatalanib × Dermatologic × Clear all

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1 Thoracic 1 Sarcoma 1 Other solid neoplasm 1 Other hematologic neoplasm 1 Myeloid 1 Genitourinary 1 Gastrointestinal 1 Dermatologic 1 CNS 1 Breast 1

Conditions

Interventions

pembrolizumab 66 Nivolumab 48 Ipilimumab 37 Cyclophosphamide 33 aldesleukin 25 Interleukin-2 20 fludarabine 16 fludarabine phosphate 15 Temozolomide 15 trametinib 10 dabrafenib 10 Radiotherapy 10 Biopsy 10 avelumab 8 Bevacizumab 8 sargramostim 7 cemiplimab 7 Paclitaxel 7 Cisplatin 7 lenvatinib 6 Magnetic Resonance Spectroscopy 6 Fluorouracil 6 Dacarbazine 6 spartalizumab 5 poly ICLC 5 montanide ISA 51 5 Specimen Handling 5 Radiosurgery 5 Peripheral Blood Stem Cell Transplantation 5 Granulocyte-Macrophage Colony-Stimulating Factor 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00615160 2021-10-06

PTK/ZK in Disseminated Malignant Melanoma

University Hospital Schleswig-Holstein

Phase 1/2 Terminated

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡